Follows pregnant people with migraine who take rimegepant
Tracks outcomes for mothers, fetuses and infants after rimegepant exposure.
Key facts
- Who runs it
- Pfizer
- Where
- Wilmington, United StatesSee the site
- Trial code
- Registry title
- Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant
- Status
- Recruiting
- People taking part
- 780 people, planned
- Started
- 23 Sept 2021
- Expected to end
- 30 Apr 2034
- Type of study
- Observational, 2 groups
- Treatments tested
- Rimegepant
- Not taking Rimegepant
- Record updated
- 29 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for pregnant women with migraine. One group took rimegepant during or just before pregnancy. The other group did not take it.
- Age
- The record gives a minimum age of 0 years and no upper limit.
- Sex
- Women only.
- Disease stage
- A diagnosis of migraine, during pregnancy.
- Earlier treatment
- Exposed group: at least 1 dose of rimegepant during pregnancy or up to 3 days before conception. Comparison group: no rimegepant before or during pregnancy.
Main reasons for not taking part
- Women who took other CGRP antagonists (for example ubrogepant) during pregnancy or just before it
- Women who took CGRP monoclonal antibodies during pregnancy or just before it
- Women who took ditans (for example lasmiditan) during pregnancy or just before it
This trial only enrols pregnant participants. The registry sentence this rests on: Pregnant women with migraine exposed to rimegepant: a diagnosis of migraine and at least 1 dose of rimegepant during pregnancy or just prior to pregnancy (up to 3 days prior to conception)
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- Pregnant women with migraine exposed to rimegepant: a diagnosis of migraine and at least 1 dose of rimegepant during pregnancy or just prior to pregnancy (up to 3 days prior to conception)
- Pregnant women with migraine unexposed to rimegepant: a diagnosis of migraine and no exposure to Rimegepant before or during pregnancy
Who cannot take part
- Women exposed to other calcitonin gene-related peptide (CGRP)antagonists (e.g., ubrogepant), CGRP monoclonal antibodies, or ditans (e.g., lasmiditan) at any time during pregnancy or just prior to pregnancy
Where in United States
- Evidera, a PPD business unitWilmington, United StatesTaking people
About the trial
What the trial wants to find out
The purpose of the study is to evaluate fetal, maternal, and infant outcomes through 12 months of age.
The 2 groups in the trial
- Pregnant women with migraine exposed to Rimegepant
Pregnant women with a diagnosis of migraine who are exposed to rimegepant at any time during pregnancy or just prior to pregnancy (up to 3 days prior to conception)
Treatment: Rimegepant
- Pregnant women with migraine not exposed to Rimegepant
Pregnant women with a diagnosis of migraine who are not exposed to rimegepant (up to 5 product half-lives prior to conception) but who may be exposed to other products for the treatment/prevention of migraine at any time during pregnancy or just prior to pregnancy
Treatment: Not taking Rimegepant
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Prospective, Registry-based, Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant: The Migraine Observational Nurtec Pregnancy Registry (MONITOR)
- Plain-language title
- Follows pregnant people with migraine who take rimegepantGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 29 October 2026